SGS opening new biopharma testing lab in Geneva

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Zmaj88)
(Image: Getty/Zmaj88)

Related tags: SGS, Biopharmaceutical, Analytical chemistry, Bioanalytical, Laboratory

The analytical and bioanalytical contract solutions provider SGS is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland.

SGS​ also provides Phase I-IV clinical trial management, with services including data management and statistics, PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation, pharmacovigilance, and regulatory consultancy.

The new 200 square meter laboratory, slated to open by the end of Q3 2018, will be equipped with several instruments and complements the company’s existing 800 square meter facility.

Upon completion, the laboratory will offer full ICH Q6B​ physico-chemical characterization of biological products.

According to SGS, the expansion responds to the “growing need for biopharmaceutical studies during the early and late phase of characterization, as required by the ICH guidelines.”

Services to be offered include circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS), and differential scanning calorimetry (DSC).

“To fulfil regulatory requirements, the biopharmaceutical industry increasingly expects its contract service providers to offer comprehensive characterization capabilities from a single location,”​ said Luc-Alain Savoy, managing director of SGS Life Sciences Geneva in a press release.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more